Skip to main content
Premium Trial:

Request an Annual Quote

Seven Bridges Raises $15M in First Closing of Series C

NEW YORK – Seven Bridges Genomics said Tuesday that it has raised $15 million from a new investor in the first closing of a planned $30 million Series C round of venture capital. The Boston-based multiomic bioinformatics company did not disclose the name of the investor but said it was a new shareholder that works in life sciences.

Seven Bridges said that the second half of the round is expected to close before the end of the second quarter.

"Multiomics tools are fast becoming ubiquitous drivers of scientific innovation," Seven Bridges CEO William Moss said in a statement. "This new investment … will help us continue to innovate and scale our organization to serve our customers’ rapidly evolving needs to utilize multiomics data in their research."

The firm has brought in about $113 million in venture capital since its inception in 2009. Seven Bridges raised $3 million in a seed round in 2014, $45 million in a Series A round in 2016, and $50 million in a Series B round in 2018.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.